2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2132

Short-Run Transitions In Pain States: Reflections Of Multiple Outcome Clinical Measures of Inadequate Pain Relief among Patients With Knee Osteoarthiritis
Abstract Number: 2426

Signaling Abnormalities In Neutrophil Granulocytes Of Rheumatoid Arthritis Patients Are Associated With Increased Extracellular Trap Formation and Provide a Basis For The Induction Of Anti-Citrullinated Peptide Antibodies
Abstract Number: 1341

Significantly Less Glucocorticoids and Better Patient-Reported Outcomes In Women With Early Inflammatory Arthritis Using Oral Contraceptives Compared To Never Users
Abstract Number: 2650

Silent Ischemic Heart Disease In Patients With Primary Antiphospholipid Syndrome
Abstract Number: 2172

Single MVK Mutation and Recurrent Fevers
Abstract Number: 789

Sirolimus Plus Prednisone For Erdheim-Chester Disease: A Pilot Trial
Abstract Number: 503

Sjögren’s Syndrome In American Ethnic and Racial Minorities
Abstract Number: 141

Skin Disease and Fibromyalgia: Dermatologic Diagnoses Encountered In a Series Of 845 Patients With Fibromyalgia At Mayo Clinic In 2008
Abstract Number: 1863

SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Abstract Number: 25

SLE Flares Are Characterized By Generalized Polyclonal Expansions Of Antibody Secreting Cells Without Preference For Autoimmune Responses
Abstract Number: 389

Small Intestine Enteropathy In Patients With Rheumatoid Arthritis and Osteoarthritis, Taking Regularly Non-Steroidal Antirheumatic Drugs . Has The Basic Disease Effect On Incidence and Degree Of Damage?
Abstract Number: 901

Smokers and Overweight Persons Are At Increased Risk Of New Onset Of Severe Foot Pain and Persistent Severe Foot Pain In a Population Study
Abstract Number: 2260

Smoking and Antibodies To Cyclic Citrullinated Peptides Predict Persistently High Levels Of Survivin In Early Rheumatoid Arthritis
Abstract Number: 1512

Smoking and Its Relationship With Clinical, Radiological and Functional Status In Patients With Ankylosing Spondylitis
Abstract Number: 625

Smoking and Secondhand Smoke Exposure Among Patients With Systemic Lupus Erythematosus and Controls: Associations With Disease and Disease Damage

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].